Document is current
Any future updates will be listed below
-
Authors
Upadhyaya, Himanshu P.
Chien, Jenny Y.
Long, Amanda J.
Bohm, Martin S.
Kallewaard, Nicole L.
Macpherson, Lisa F.
Patel, Dipak R.
Hufford, Matthew M.
Krull, Constance J.
Ang, Jocelyn Y.
Chen, Peter
Muller, William J.
Potts, Jeffrey A.
Quinn, Timothy
Williams, Mark
,
Amin, Faisal
Azizad, Masoud
Belden, Katherine
Boscia, Joseph
Bukhman, Yevgeniy
Cardona, Jose
Chen, Peter
Cook, Paul
Crystal, Chad
Dougan, Mike
Fischer, William
Glassberg, Jeffrey
Gottlieb, Robert L.
Herbert, Corey
Huang, Howard
Huhn, Gregory
Kingsley, Jeffery
Kumar, Princy
Malik, Anuj
Malvestutto, Carlos
Milligan, Patrick
Mocherla, Bharat
Mohseni, Ramesh
Morris, Jason
Nathan, Ramesh
Pitrak, David
Purow, Joshua
Ramesh, Mayur
Sachdeva, Yessica
Schwartz, Adam
Shawa, Imad
Sobh, Nader
Stosor, Valentina
Thompson, Charles
Verma, Omesh
West, Erica Kaufman
Wheeler, David
Winnie, Michael
Zeno, Brian
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04427501 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial
https://doi.org/10.1007/s40121-023-00832-y
Safety, tolerability, pharmacokinetic characteristics, and immunogenicity of MW33: a Phase 1 clinical study of the SARS-CoV-2 RBD-targeting monoclonal antibody
https://doi.org/10.1080/22221751.2021.1960900
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 15 March 2023
Accepted: 30 May 2023
First Online: 17 June 2023
